Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Signpath Pharma Inc. operates within the Biotechnology & Pharmaceuticals technology area. The company has 2 pending office actions currently under review. These actions are spread across 2 distinct examiners and 2 distinct art units, reflecting a varied prosecution environment. This distribution suggests that the company's pharmaceutical innovations are being evaluated from different technical perspectives within the Biotechnology & Pharmaceuticals field.
O DELL, DAVID K is the busiest examiner for the portfolio, with 1 pending office action. Since the company has 2 pending office actions in total, O DELL, DAVID K is responsible for 1 of the current prosecution matters. The presence of 2 distinct art units suggests that the company's innovations are being evaluated under different sets of examination criteria, which may require distinct legal strategies for each case. This diversity in the prosecution landscape provides a broader base for the company's intellectual property development.
For a patent practitioner, the distribution of 2 pending office actions across 2 distinct examiners means that there is no single point of focus for the portfolio. Each application must be managed according to the specific requirements of its assigned examiner and art unit. This variety in the examination process requires a coordinated approach to successfully navigate the different paths presented by the 2 distinct art units and the multiple examiners involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18457037 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | O DELL, DAVID K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18457037 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | O DELL, DAVID K | — |
| 18260012 | LIPIDS THAT REDUCE LUNG DAMAGE, IMPROVE PULMONARY FUNCTION AND DECREASE PRO-INFLAMMATORY CYTOKINES | RODRIGUEZ, RAYNA B | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18457037 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | O DELL, DAVID K | 1621 | §102§112 | Final Rejection | — | Pending | Aug 28, 2023 |
| 18260012 | LIPIDS THAT REDUCE LUNG DAMAGE, IMPROVE PULMONARY FUNCTION AND DECREASE PRO-INFLAMMATORY CYTOKINES | RODRIGUEZ, RAYNA B | 1628 | §112 | Final Rejection | — | Pending | Jun 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSignpath Pharma Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
David K O Dell has the most, with 1 of Signpath Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
